Streetbeat News

Analyst Ratings

VST

Vistra (NYSE:VST) has received varied ratings from 9 analysts, with a majority being somewhat bullish. The average 12-month price target has increased by 20.89% to $138.33. Analysts have adjusted their ratings and price targets, reflecting positive sentiment towards Vistra's market position and financial performance.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:01 pm

ALV

Autoliv (NYSE:ALV) is set to release its quarterly earnings on October 18, 2024. Analysts expect an EPS of $1.95. The company's past performance shows mixed results, with a recent EPS miss leading to a stable share price. Analysts have a Neutral rating on Autoliv, with a price target suggesting a potential 26.24% upside. Autoliv's financials show challenges in revenue growth and net margin, but strong ROE and ROA. The company's debt management is favorable compared to industry averages.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:01 pm

GO

Grocery Outlet Holding (NASDAQ:GO) has been analyzed by 7 analysts, showing a range of sentiments from bullish to bearish. The average 12-month price target has decreased by 23.57% to $21.86, with a high of $31.00 and a low of $17.00. Analysts have adjusted their ratings and price targets, reflecting a negative shift in sentiment. Despite this, Grocery Outlet Holding shows strong financial metrics, including a positive revenue trend and strong profitability indicators.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:01 pm

AXP

American Express (NYSE:AXP) is set to release its quarterly earnings on October 18, 2024. Analysts expect an EPS of $3.28. The company's past performance shows mixed stock price reactions to earnings beats. Currently, AXP has a Neutral consensus rating with a potential downside based on the average price target. The company's strong revenue growth and financial metrics position it well among peers.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:01 pm

SR

Analysts have mixed ratings for Spire (NYSE:SR), with recent evaluations showing a shift towards bearish sentiment. The average 12-month price target has increased slightly to $69.88. Spire faces financial challenges, including a decline in revenue and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

JKHY

Jack Henry & Associates (NASDAQ:JKHY) has been analyzed by five analysts, showing a range of sentiments from somewhat bullish to indifferent. The average 12-month price target is $189.6, up 4.46% from the previous target. Analysts have adjusted their ratings and price targets, reflecting their views on the company's market position. Jack Henry is a leading provider of core processing services for banks and credit unions, with strong net margins and efficient asset use, but faces challenges in revenue growth and return on equity.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

PG

Procter & Gamble (NYSE:PG) is set to release its quarterly earnings report on October 18, 2024, with analysts estimating an EPS of $1.90. Despite a previous earnings beat, the stock saw a slight decline, highlighting the importance of future projections. Analysts have a Neutral consensus on PG, with a slight potential upside. The company's revenue growth lags behind peers, but it maintains strong net margins and effective debt management.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

CCI

Crown Castle (NYSE:CCI) has been analyzed by 8 analysts, showing a range of ratings from bullish to indifferent. Recent analyst actions include both raised and lowered price targets, with an average 12-month target of $116.75, up 4.35% from the previous average. Despite positive analyst sentiment, Crown Castle faces financial challenges, including a -12.91% revenue decline, low net margin, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm

SDGR

BMO Capital analyst Gary Nachman maintains an Outperform rating on Schrodinger (NASDAQ:SDGR) but lowers the price target from $30 to $25.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:00 pm

LXRX

Lexicon Pharmaceuticals (NASDAQ:LXRX) has been evaluated by 8 analysts over the past three months, with all ratings being bullish. The average 12-month price target remains at $10.00. Despite strong revenue growth, the company faces challenges with profitability and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 2:00 pm